Interacción de Losartán con Quinapril e hidroclorotiazida
Losartán con Quinapril e hidroclorotiazida: ambas etiquetas de prescripción describen una interacción que por lo general requiere seguimiento, un cambio de dosis o espaciar las tomas.
Por lo general, manejable con seguimiento o un cambio de dosis. Informe a su farmacéutico de que toma ambos.
Qué dicen las etiquetas de la FDA
De la etiqueta de Losartán (COZAAR) · vigente desde 2026-01-20
Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR.
NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists (including losartan)…
Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.
Renal Function Deterioration Changes in renal function including acute renal failure can be caused by drugs that inhibit the renin-angiotensin system and by diuretics.
De la etiqueta de Quinapril e hidroclorotiazida (Quinapril and Hydrochlorothiazide) · vigente desde 2023-12-11
The thiazide component of quinapril and hydrochlorothiazide tablets may potentiate the action of other antihypertensive drugs, especially ganglionic or peripheral adrenergic- blocking drugs.
Quinapril and hydrochlorothiazide tablets should be used cautiously in patients receiving concomitant therapy with other antihypertensives.
Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents.
¿Toma algo más además de estos dos? Las interacciones se acumulan. Compruebe toda su lista de una vez; se queda en su navegador.
Abrir en el verificadorNo es un consejo médico. Interaction Checker cita el texto de las etiquetas de la FDA y las hojas informativas de los NIH. Que una interacción sea importante en su caso depende de las dosis, el momento de las tomas, la función renal y hepática y otras afecciones. Confírmelo con un farmacéutico o un prescriptor.